<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        23-355-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TAMOXIFEN 10MG EBEWE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAMOXIFEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HAUPT PHARMA AMAREG GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HAUPT PHARMA AMAREG GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is Tamoxifen</strong><br />Tamoxifen Tablets contain a medicine called tamoxifen. This belongs to a group of medicines called &lsquo;anti-estrogens&rsquo;.</p><p><strong>What it is used for</strong><br />Tamoxifen is used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of infertility in women caused by a failure to produce and release eggs (ovulate) properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tamoxifen Tablets can also reduce the risk of developing breast cancer occurring in those women who have an increased likelihood of developing breast cancer.</p><p>&nbsp;</p><p><strong>How Tamoxifen Tablets work</strong><br />Estrogen is a natural substance in your body known as a &lsquo;sex hormone&rsquo;. Some breast cancers need estrogen to grow and tamoxifen works by blocking the effects of estrogen.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Tamoxifen Tablets: </strong><br />&bull; if you are allergic to tamoxifen or any of the other ingredients of this medicine (listed in section 6) &bull; if you are pregnant or think you might be pregnant (see the section on &lsquo;Pregnancy&rsquo; below).<br />&bull; if you are taking anastrozole.<br />&bull; if you are taking any treatment for infertility.<br />&bull; if you have had blood clots in the past and the doctor did not know what caused them.<br />&bull; if someone in your family has had blood clots with the cause not known.<br />&bull; if your doctor has told you that you have an illness which runs in the family that increases<br />&nbsp;&nbsp; the risk of blood clots.<br />&nbsp;&bull; if you are taking medicines used to prevent blood clots such as warfarin.</p><p><br />Do not take Tamoxifen Tablets if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Tamoxifen Tablets.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Tamoxifen Tablets.</p><p><strong>&nbsp;</strong></p><p>1. Tamoxifen therapy may be used to reduce the risk of breast cancer and it can be associated with serious side effects such as blood clots in the veins of your leg (deep vein thrombosis), blood clots in your lungs (pulmonary embolus) and uterine cancer, all of which can be fatal. Other less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities and pelvis pain may also occur. Whether the benefits of treatment outweigh the risks depends on your age, health history, your level of breast cancer risk and on your personal judgement. Tamoxifen therapy to reduce the risk of breast cancer may not be appropriate for all women at increased risk. All assessments with your healthcare professional of the potential benefits and risks prior to starting therapy are essential. You should understand that tamoxifen reduces, but does not eliminate the risk of breast cancer.</p><p>&nbsp;</p><p>2. If you are to undergo planned surgery, you should tell your doctor or pharmacist as they may wish to consider stopping your treatment for a short period.</p><p>&nbsp;</p><p>3. Women of child-bearing age should be instructed to utilize adequate non-hormonal contraception (e.g. barrier contraception) during treatment with tamoxifen and for 2 months after stopping treatment.</p><p>&nbsp;</p><p><strong>Other medicines and Tamoxifen Tablets</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines you buy without a prescription and herbal medicines. This is because Tamoxifen Tablets can affect the way some other medicines work and some medicines can have an effect on Tamoxifen Tablets.</p><p>In particular, you should tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Oral contraceptives<br />&bull; Hormone replacement therapy (HRT)<br />&bull; Antidepressants (e.g. paroxetine, fluoxetine).<br />&bull; Bupropion (used as antidepressant or aid to smoking cessation).<br />&bull; Quinidine (for example used in the treatment of cardiac arrhythmia).<br />&bull; Cincalet/Cinacalcet (for treatment of disorders of the parathyroid gland).<br />&bull; Blood thinning medicines such as warfarin. These are known as &lsquo;anti-coagulants&rsquo;.<br />&bull; Rifampicin, which is used for tuberculosis (TB).<br />&bull; Medicines known as &lsquo;aromatase inhibitors&rsquo; that are used to treat breast cancer. These include<br />&nbsp;&nbsp; anastrozole, letrozole and exemestane.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><br /><strong>Pregnancy </strong><br />&bull; Do not take Tamoxifen Tablets if you are pregnant. This is because it may affect your unborn<br />&nbsp;&nbsp; baby.</p><p>&bull; You should not become pregnant while taking Tamoxifen Tablets. Please see your doctor for<br />&nbsp;&nbsp; advice on what contraceptive precautions you should take, as some may be affected by<br />&nbsp;&nbsp; Tamoxifen Tablets.</p><p>&bull; You should see your doctor immediately if you think you may have become pregnant after<br />&nbsp;&nbsp; starting to take Tamoxifen Tablets.</p><p><br /><strong>Breast-feeding</strong><br />Talk to your doctor before taking Tamoxifen Tablets if you are breast-feeding.<br /><br /><strong>Driving and using machines</strong><br />Tamoxifen Tablets are not likely to affect your ability to drive or use any tools or machines. However, tiredness has been reported with the use of Tamoxifen Tablets and caution should be observed when driving or operating machinery while such symptoms persist.</p><p>&nbsp;</p><p><strong>Tamoxifen Tablets contain lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product as it contains lactose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />&nbsp;</p><p><strong>Breast cancer treatment </strong></p><p>The recommended dose for breast cancer is 20mg daily.</p><p>&nbsp;</p><p><strong>Infertility</strong></p><p>The dose for infertility depends on your periods (menstrual cycle).</p><p>&bull; If you are having regular periods, the recommended dose is one 20mg tablet daily on the 2nd,<br />&nbsp;&nbsp; 3rd, 4th and 5th days of your period.</p><p>&bull; If this does not work, your doctor may suggest that you take a higher dose of Tamoxifen<br />&nbsp;&nbsp; Tablets during your next period. If this happens, the recommended dose is 40mg or 80mg daily<br />&nbsp;&nbsp; on the 2nd, 3rd, 4<sup>th</sup> and 5th days of your period.</p><p>&bull; If you are not having regular periods, you can start taking the tablets on any day of the month.</p><p>&nbsp;</p><p><strong>Reducing the risk of breast cancer </strong></p><p>The recommended dose for reducing the risk of breast cancer is 20 mg daily for 5 years.</p><p>Your healthcare professional will calculate your risk of breast cancer occurring using information about you, your medical history and any family history of breast cancer.</p><p>&nbsp;</p><p><strong>If you take more Tamoxifen Tablets than you should </strong></p><p>If you take more Tamoxifen Tablets than you should, talk to a doctor or pharmacist straight away.</p><p>&nbsp;</p><p><strong>If you forget to take Tamoxifen Tablets </strong></p><p>If you forget to take a dose, take another as soon as you remember. However, if it is nearly time for the next dose skip the missed dose. Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>Stopping treatment with Tamoxifen Tablets </strong></p><p>You should continue to take Tamoxifen Tablets for as long as your doctor tells you to. Do not stop taking the medicine without talking to your doctor first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop taking Tamoxifen Tablets and tell your doctor straight away if you notice any of the following side effects &ndash; you may need urgent medical treatment: </strong></p><p>&bull; Symptoms of a blood clot. These include swelling of the calf or leg, chest pain, being short of breath or<br />&nbsp;&nbsp; suddenly feeling weak.</p><p>&bull; Symptoms of a stroke. These include sudden onset of the following: weakness or paralysis of the arms<br />&nbsp;&nbsp; or legs, being unable to move the arms or legs, sudden difficulty with speaking, walking, difficulty in<br />&nbsp;&nbsp; holding things or difficulty in thinking. These symptoms are caused by a reduced blood supply in the<br />&nbsp;&nbsp; brain.</p><p>&bull; Difficulty in breathing.</p><p>&bull; Swelling of the face, lips, tongue or throat which may make it difficult to swallow.</p><p>&bull; Swelling of the hands, feet or ankles.</p><p>&bull; Nettle rash (also called &lsquo;hives&rsquo; or &lsquo;urticaria&rsquo;).</p><p>&nbsp;</p><p><strong>Tell your doctor straight away if you notice any of the following: </strong></p><p>&bull; Unusual bleeding from your vagina.</p><p>&bull; Irregular periods, especially if associated with heavier bleeding as this could be a warning sign for a<br />&nbsp;&nbsp; certain type of cancer affecting the lining of your womb (endometrial cancer).</p><p>&bull; Vaginal discharge.</p><p>&bull; A feeling of discomfort in the lower tummy (pelvis) such as pain or pressure. These effects may mean<br />&nbsp;&nbsp; that there have been changes to the lining of your womb (the endometrium). Sometimes these effects<br />&nbsp;&nbsp; are serious and could include cancer. They can happen during or after treatment with Tamoxifen<br />&nbsp;&nbsp; Tablets.</p><p>&nbsp;</p><p><strong>Other possible side effects: </strong></p><p><strong>Very common: may affect more than 1 in 10 people </strong></p><p>&bull; Nausea.</p><p>&bull; Fluid retention.</p><p>&bull; Skin rash.</p><p>&bull; Hot flushes.</p><p>&bull; Tiredness.</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&bull; Anemia (a blood problem which means you have too few red blood cells).</p><p>&bull; Changes in vision due to cataracts or changes to the retina of your eye.</p><p>&bull; Increased amounts of fats in your blood (shown by blood tests).</p><p>&bull; Allergic reactions.</p><p>&bull; Leg cramp.</p><p>&bull; Changes in the womb (including changes to its lining and benign growths).</p><p>&bull; Headache.</p><p>&bull; Feeling light-headed.</p><p>&bull; Itching of the genitals.</p><p>&bull; Thinning of the hair.</p><p>&bull; Vomiting.</p><p>&bull; Diarrhea.</p><p>&bull; Constipation.</p><p>&bull; Changes in blood tests of liver function.</p><p>&bull; Formation of fatty liver cells.</p><p>&bull; Muscle pain.</p><p>&bull; Sensory changes (including taste disorder and numbness or tingling in the skin).</p><p>&bull; Increased risk of blood clots (including clots in small vessels).</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people </strong></p><p>&bull; Blood problems. This can make you bruise more easily, get serious infections, or feel very tired or<br />&nbsp;&nbsp; breathless.</p><p>&bull; Changes to your vision and difficulty seeing.</p><p>&bull; Swelling of the pancreas. This may cause moderate to severe pain in the stomach.</p><p>&bull; Changes in the amount of calcium in your blood. The signs may include feeling very sick, being sick a<br />&nbsp;&nbsp; lot or being thirsty. <strong>Tell your doctor if this happens</strong> because he or she may want you to have blood<br />&nbsp;&nbsp; tests.</p><p>&bull; Inflammation of the lungs. The symptoms may be like pneumonia (such as feeling short of breath and<br />&nbsp;&nbsp; coughing).</p><p>&bull; Liver cirrhosis (problems with your liver).</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people </strong></p><p>&bull; Severe blood problems. This can make you bruise more easily, get serious infections, or feel very tired<br />&nbsp;&nbsp; or breathless.</p><p>&bull; Changes to the cornea of your eye.</p><p>&bull; Problems with the nerve that connects your retina to your brain.</p><p>&bull; Swelling of the optic nerve.</p><p>&bull; On occasions more severe liver diseases have occurred from which some patients have died. These liver<br />&nbsp;&nbsp; diseases include inflammation of the liver, liver cirrhosis, liver cell damage, reduced bile formation, and<br />&nbsp;&nbsp; failure of the liver. Symptoms may include a general feeling of being unwell, with or without jaundice<br />&nbsp;&nbsp; (yellowing of the skin and eyes).</p><p>&bull; A severe rash with blisters or peeling of the skin and possibly blisters in the mouth and nose (Stevens-<br />&nbsp;&nbsp; Johnson syndrome).</p><p>&bull; Damage to blood vessels causing red or purple dots in the skin.</p><p>&bull; Severe skin disorder. The symptoms include redness, blistering and peeling.</p><p>&bull; Cells normally only found in the lining of the womb found elsewhere in your body, cysts on the ovaries,<br />&nbsp;&nbsp; and cancer (the signs of this are given above).</p><p>&bull; Non-cancerous mass in the inner lining of the vagina (called vaginal polyp).</p><p>&bull; At the beginning of treatment, a worsening of the symptoms of your breast cancer such as an increase in<br />&nbsp;&nbsp; pain and/or an increase in the size of the affected tissue may occur (known as tumor flare).</p><p>&nbsp;</p><p><strong>Very rare: may affect up to 1 in 10,000 people </strong></p><p>&bull; Inflammation of the skin characterized by rash or erythema, very often on areas exposed to light (a<br />&nbsp;&nbsp; condition called cutaneous lupus erythematosus)</p><p>&bull; A skin condition characterized by skin blisters in areas exposed to the light, this is due to the increased<br />&nbsp;&nbsp; liver production of a special group of cell pigments (called porphyrins)</p><p>&bull; Radiation recall - skin rash involving redness, swelling, and/or blistering (like severe sunburn) of the<br />&nbsp;&nbsp; skin after receiving radiation therapy.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and foil. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice visible signs of deterioration such as discoloration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 25&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original container or package to protect from light and moisture. Do not transfer the tablets to another container.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is tamoxifen citrate</p><p>1 film-coated tablet contains 15,2 mg tamoxifen citrate (corresponding to 10 mg tamoxifen).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:<br />microcrystalline cellulose, lactose monohydrate, magnesium stearate (Ph.Eur.), maize starch, colloidal anhydrous silica.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The film-coated tablets are white, round and convex.

Tamoxifen “EBEWE” 10 mg is available in packs containing 30 or 100 film-coated tablets.


Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBEWE PHARMA GES.M.B.H NFG. KG,</p><p>UNTERACH,</p><p>AUSTRIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُعد عقار تاموكسيفين 10 مجم &quot;إيبيفيه&quot; على دواء يسمى تاموكسيفين. هذا ينتمي إلى مجموعة من الأدوية تسمى &quot;مضادات الاستروجين&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستخدم عقار تاموكسيفين </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot; 10 </strong><strong>مجم في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج سرطان الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج العقم عند النساء بسبب الفشل في إنتاج وإطلاق البويضات (الإباضة) بشكل صحيح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تقلل أقراص تاموكسيفين من خطر الإصابة بسرطان الثدي لدى النساء اللائي لديهن احتمال متزايد للإصابة بسرطان الثدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تعمل عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم</strong></p><p dir="RTL">الاستروجين هو مادة طبيعية في جسمك تعرف باسم &quot;هرمون الجنس&quot;. تحتاج بعض أنواع سرطان الثدي إلى نمو هرمون الاستروجين ويعمل عقار تاموكسيفين عن طريق منع آثار هرمون الاستروجين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا&nbsp;تتناول عقار تاموكسيفين &quot;إيبيفيه 10 مجم&quot; في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه سترات التاموكسيفين أو أحد المكونات الأخرى بهذا المنتج الدَّوائي المُدرجة في قسم: 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو مرضعًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي علاج للعقم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ أناستروزول.</p><p>إذا كنت قد أصبت بجلطات دموية في الماضي ولم يعرف الطبيب سببها&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</p><p>إذا كان شخص ما في عائلتك مصابًا بجلطات دموية لم يعرف السبب&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك أن لديك مرضًا يتزايد في العائلة و يزيد خطر جلطات الد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية المستخدمة لمنع جلطات الدم مثل الوارفارين</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ أقراص تاموكسيفين إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا ، فتحدث إلى طبيبك أو الصيدلي قبل تناول أقراص تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار تاموكسيفين &quot;إيبيفيه 10 مجم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام علاج تاموكسيفين لتقليل خطر الإصابة بسرطان الثدي ويمكن أن يرتبط بآثار جانبية خطيرة مثل جلطات الدم في أوردة ساقك (تجلط الأوردة العميقة) ، والجلطات الدموية في رئتيك (الصمة الرئوية) وسرطان الرحم ، وكلها يمكن أن تكون قاتلة. قد تحدث آثار جانبية أخرى أقل خطورة مثل الهبات الساخنة ، والإفرازات المهبلية ، والمخالفات الشهرية وآلام الحوض. ما إذا كانت فوائد العلاج تفوق المخاطر يعتمد على عمرك وتاريخك الصحي ومستوى خطر الإصابة بسرطان الثدي وعلى حكمك الشخصي. قد لا يكون علاج عقار تاموكسيفين لتقليل خطر الإصابة بسرطان الثدي مناسبًا لجميع النساء المعرضات لخطر متزايد. جميع التقييمات مع أخصائي الرعاية الصحية الخاص بك من الفوائد والمخاطر المحتملة قبل بدء العلاج ضرورية. يجب أن تفهم أن عقار تاموكسيفين يقلل ، ولكن لا يلغي خطر الإصابة بسرطان الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعملية جراحية مخططة ، يجب عليك إخبار طبيبك أو الصيدلي لأنه قد يرغب في إيقاف علاجك لفترة قصيرة.</p><p>&nbsp;</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي توجيه النساء في سن الإنجاب إلى استخدام وسائل منع الحمل غير الهرمونية الكافية (مثل منع الحمل الحاجز) أثناء العلاج باستخدام عقار تاموكسيفين ولمدة شهرين بعد توقف العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>تناوُل عقار تاموكسيفين </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot; 10 </strong><strong>مجم مع مُنتَجات دوائية أخرى</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول ، أو اتخذت مؤخرا أو قد تأخذ أي أدوية أخرى. وهذا يشمل الأدوية التي تشتريها بدون وصفة طبية والأدوية العشبية. وذلك لأن أقراص تاموكسيفين يمكن أن تؤثر على طريقة عمل بعض الأدوية الأخرى وبعض الأدوية يمكن أن يكون لها تأثير على أقراص تاموكسيفين.</p><p dir="RTL">على وجه الخصوص ، يجب أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من الأدوية التالية :</p><p dir="RTL">وسائل منع الحمل عن طريق الفم</p><p dir="RTL">العلاج بالهرمونات البديلة</p><p dir="RTL">مضادات الاكتئاب (مثل الباروكستين ، فلوكستين).</p><p dir="RTL">البوبروبيون (يستخدم كمضاد للاكتئاب أو يساعد في الإقلاع عن التدخين).</p><p dir="RTL">الكينيدين (على سبيل المثال يستخدم في علاج عدم انتظام ضربات القلب).</p><p dir="RTL">Cincalet / Cinacalcet (لعلاج اضطرابات الغدة الدرقية).</p><p dir="RTL">أدوية ترقق الدم مثل الوارفارين. وتعرف هذه باسم &quot;مضادات التخثر&quot;.</p><p dir="RTL">ريفامبيسين ، والذي يستخدم لمرض السل (السل).</p><p dir="RTL">الأدوية المعروفة باسم &quot;مثبطات الهرمونات&quot; التي تستخدم لعلاج سرطان الثدي. وتشمل هذه</p><p dir="RTL">&nbsp;أناستروزول ، يتروزول وإكسيميستان</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار النَّاجمة عند سوء استخدام العقار لأغراض المنشطات</strong></p><p dir="RTL">من الممكن أن يُؤدي استخدام عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم إلى نتائج إيجابية في فحوصات الكشف عن المنشطات. من غير المُمكِن التنبؤ بالعواقب الصحية المترتبة على استخدام عقار تاموكسيفين كمادة مُنَشِّطة؛ وبالتالي لا يُمكِن استبعاد المخاطر الصحية الخطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تجنُّب التَّناوُل المُتزامِن لمنتجات دوائية أخرى بها المواد الفعَّالة التَّالية؛ إذ لا يُمكِن استبعاد حدوث انخفاض في فعَّالية عقار تاموكسيفين: باروكسيتين، فلوكسيتين (على سبيل المثال، لعلاج الاكتئاب)، بُوبْرُوبْيُون (لعلاج الاكتئاب أو للمساعدة في الإقلاع عن التَّدخين)، كينيدين (على سبيل المثال، لعلاج اضطرابات النظم القلبي) وسيناكالسيت (لعلاج اضطرابات الغدة المجاورة للدرقية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلِغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تستخدم مُنتَجًا دوائيًّا آخر، أو إذا تناولت أو استخدمت مؤخرًا أو تنوي تناوُل أو استخدام مُنتَج دوائي آخر. أبلِغ طبيبك إذا كنت تتناول/تستخدم أيًّا من المنتجات الدَّوائية/المواد الفعالة التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باروكسيتين، فلوكسيتين (على سبيل المثال، لعلاج الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بُوبْرُوبْيُون (لعلاج الاكتئاب أو للمساعدة في الإقلاع عن التَّدخين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (على سبيل المثال، لعلاج اضطرابات النظم القلبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيناكالسيت (لعلاج اضطرابات الغدة المجاورة للدرقية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتأثر فعَّالية المواد الدَّوائية أو فئات المُنتَجات المُدرَجة أدناه بالعلاج المُتزامِن مع عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أدوية قد يتم تعزيز تأثيراتها إلى حد وجود احتمالية أكبر للتعرُّض لخطر الآثار الجانبية</u><u>:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المُنتجات الدَّوائية المضادة للتجلُّط. لا تتناول عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم بمصاحبة هذه الأدوية إلا إذا أعطاك طبيبك تعليمات صريحة بفعل ذلك. يجب مراعاة مواعيد اختبارات الدَّم بدقة بسبب زيادة القابلية لحدوث نزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الكيميائي المتزامن. هناك مؤشرات على أنَّ جلطات الدَّم قد تزيد أثناء العلاج بعقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم (مما ينتج عنه أحداث الانصمام الخثاري، بما في ذلك، الخثار الوريدي العميق والانصمام الرئوي). يزداد معدّل التكرار مع العلاج الكيميائي المتزامن.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><u>أدوية يُمكِن أن تنخفض تأثيراتها</u><u>:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المستحضرات الهرمونية، وخاصة التي تحتوي على الإستروجين (على سبيل المثال: &quot;حبوب منع الحمل&quot;). قد تقلل المنتجات الدَّوائية تأثيرات بعضها البعض. لذا، يجب ألا تتناول هذه المستحضرات أثناء العلاج بعقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حمل</p><p dir="RTL">&bull; لا تتناول أقراص تاموكسيفين إذا كنت حاملاً. هذا لأنه قد يؤثر على الجنين</p><p dir="RTL">&nbsp;&nbsp;&nbsp;يجب استبعاد إمكانية حدوث حمل أثناء العلاج. يرجى مراجعة طبيبك بشأن ما هي احتياطات منع الحمل التي يجب اتخاذها ، حيث قد يتأثر البعض بها&nbsp;أقراص تاموكسيفين.</p><p dir="RTL">يجب عليك مراجعة طبيبك على الفور إذا كنت تعتقد أنك قد أصبحت حاملاً بعد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;بدأت تأخذ أقراص تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول أقراص تاموكسيفين إذا كنت ترضعين طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المُحتَمَل أن يؤثر عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم في القدرة على القيادة أو استخدام الآلات. مع ذلك، تم الإبلاغ عن حدوث إرهاق أثناء العلاج بعقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم. لذلك يجب عليك توخي الحذر أثناء القيادة أو استخدام الآلات إذا أُصبت بهذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار تاموكسيفين </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot; 10 </strong><strong>مجم على سكر اللاكتوز</strong></p><p dir="RTL">إذا أخبر طبيبك بأنك لا تتحمل بعض السكريات ، فاتصل بطبيبك قبل تناول هذا المنتج الطبي لأنه يحتوي على اللاكتوز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تَناوَل دائمًا هذا المنتج الدَّوائي كما أخبرك طبيبك بالضبط</strong><strong>. </strong><strong>اسأل طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام</strong><strong>. </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>علاج سرطان الثدي&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p>الجرعة الموصى بها لسرطان الثدي هي 20 ملغ يوميا</p><p><strong>&nbsp; العقم</strong>&nbsp; &nbsp; &nbsp; &nbsp;</p><p>تعتمد جرعة العقم على دورتك الشهرية (الدورة الشهرية).</p><p>&nbsp;</p><p>إذا كان لديك دورة شهرية منتظمة، فإن الجرعة الموصى بها هي حبة واحدة بحجم 20 ملغ يوميًا في اليوم</p><p>&nbsp;&nbsp;&nbsp;الأيام الثالثة والرابعة والخامسة من دورتك الشهرية.</p><p>إذا لم ينجح ذلك ، فقد يقترح طبيبك أن تتناول جرعة أعلى من عقار تاموكسيفين</p><p>&nbsp;&nbsp;&nbsp;الأجهزة اللوحية خلال الفترة المقبلة. إذا حدث هذا ، فإن الجرعة الموصى بها هي 40 ملغ أو 80 ملغ يوميًا</p><p>&nbsp;&nbsp;&nbsp;في الأيام الثانية والثالثة والرابعة والخامسة من دورتك الشهرية.</p><p>&bull; إذا لم يكن لديك دورة شهرية منتظمة ، يمكنك البدء في تناول الأقراص في أي يوم من الشهر</p><p>&nbsp;</p><p>تقليل خطر الاصابة بسرطان الثدي</p><p>الجرعة الموصى بها للحد من خطر الاصابة بسرطان الثدي هي 20 ملغ يوميا لمدة 5 سنوات.</p><p>سيقوم أخصائي الرعاية الصحية بحساب خطر الإصابة بسرطان الثدي باستخدام المعلومات الخاصة بك وتاريخك الطبي وأي تاريخ عائلي لسرطان الثدي.</p><p>&nbsp;</p><p><strong>إذا تناولت كمية أكثر مما يجب من عقار تاموكسيفين </strong><strong>&quot;إيبيفيه</strong><strong>&quot; 10 مجم</strong></p><p>إذا كنت تأخذ أقراص تاموكسيفين أكثر مما يجب ، فتحدث إلى الطبيب أو الصيدلي على الفور.</p><p>&nbsp;</p><p><strong>إذا أغفلت تناوُل عقار تاموكسيفين </strong><strong>&quot;إيبيفيه</strong><strong>&quot; 10 مجم</strong></p><p>إذا نسيت تناول جرعة ، خذ جرعة أخرى بمجرد تذكرها. ومع ذلك ، إذا كان الوقت قد حان تقريباً للجرعة التالية ، فتخط الجرعة الفائتة. لا تأخذ جرعة مضاعفة (جرعتين في نفس الوقت) لتعويض جرعة منسية</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناوُل عقار تاموكسيفين </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot; 10 </strong><strong>مجم</strong></p><p>يجب أن تستمر في تناول أقراص تاموكسيفين طالما أخبرك طبيبك بذلك. لا تتوقف عن تناول الدواء دون التحدث إلى طبيبك أولاً.</p><p>&nbsp;</p><p>استشر طبيبك أو الصيدلي الخاص بك إذا كان لديك أسئلة أخرى حول كيفية استخدام هذا المُنتَج الدَّوائي.</p><p>&nbsp;</p><p>4.ما هي الآثار الجانبية المُحتمَلة؟</p><p>مثله مثل المُنتَجات الدَّوائية الأخرى، قد يكون لهذا المُنتَج الدَّوائي آثار جانبيةً، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>توقف عن تناول أقراص تاموكسيفين وأخبر طبيبك على الفور إذا لاحظت أيًا من الآثار الجانبية التالية - قد تحتاج إلى علاج طبي عاجل</p><p>أعراض جلطة دموية. وتشمل هذه تورم في الساق ، وألم في الصدر ، وضيق في التنفس أو</p><p>شعور فجأة بالضعف.</p><p>&nbsp;</p><p>أعراض السكتة الدماغية. وتشمل هذه بداية مفاجئة لما يلي: ضعف أو شلل الذراعين</p><p>&nbsp;&nbsp;&nbsp;أو الساقين ، عدم القدرة على تحريك الذراعين أو الساقين ، صعوبة مفاجئة في التحدث ، المشي ، صعوبة في</p><p>&nbsp;&nbsp;&nbsp;عقد الأشياء أو صعوبة في التفكير. هذه الاعراض هي سبب انخفاض امدادات الدم في</p><p>&nbsp;&nbsp;الدماغ</p><p>&nbsp;</p><p>&bull; صعوبة في التنفس.</p><p>&bull; تورم في الوجه أو الشفتين أو اللسان أو الحلق مما قد يجعل من الصعب بلعه.</p><p>&bull; تورم اليدين أو القدمين أو الكاحلين.</p><p>&bull; طفح القراص (يُطلق عليه أيضًا &quot;خلايا النحل&quot; أو &quot;الشرى&quot;).</p><p>&nbsp;</p><p>أخبر طبيبك على الفور إذا لاحظت أي مما يلي:</p><p>&bull; نزيف غير عادي من المهبل.</p><p>&bull; الدورة الشهرية التي ليست منتظمة، خاصةً إذا ارتبطت بنزيف أثقل لأن ذلك قد يكون علامة تحذير لـ</p><p>&nbsp;&nbsp;&nbsp;نوع معين من السرطان الذي يؤثر على بطانة الرحم (سرطان بطانة الرحم).</p><p>&bull; إفرازات مهبلية.</p><p>&bull; الشعور بعدم الراحة في أسفل البطن (الحوض) مثل الألم أو الضغط. هذه الآثار قد تعني</p><p>&nbsp;&nbsp;&nbsp;أن هناك تغييرات في بطانة الرحم (بطانة الرحم). في بعض الأحيان هذه الآثار</p><p>&nbsp;&nbsp;&nbsp;هي خطيرة ويمكن أن تشمل السرطان. يمكن أن يحدث أثناء أو بعد العلاج مع عقار تاموكسيفين</p><p>&nbsp;&nbsp;&nbsp;أجهزة لوحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><u>شائعة جدًّا</u> (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص تم علاجهم)</p><p>&bull; غثيان.</p><p>&bull; احتباس السوائل.</p><p>&bull; الطفح الجلدي.</p><p>&bull; الهبات الساخنة.</p><p>&bull; التعب</p><p>&nbsp;</p><p><u>شائعة</u> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص تم علاجهم).</p><p>&bull; فقر الدم (مشكلة في الدم تعني وجود عدد قليل جدًا من خلايا الدم الحمراء).</p><p>&bull; التغييرات في الرؤية بسبب إعتام عدسة العين أو التغييرات في شبكية العين.</p><p>&bull; زيادة كميات الدهون في دمك (التي تظهرها اختبارات الدم).</p><p>&bull; الحساسية.</p><p>&bull; تشنج الساق.</p><p>&bull; التغييرات في الرحم (بما في ذلك التغييرات في البطانة والنمو الحميد).</p><p>&bull; صداع الراس.</p><p>&bull; شعور خفيف الرأس.</p><p>&bull; حكة الأعضاء التناسلية.</p><p>&bull; ترقق الشعر.</p><p>&bull; القيء.</p><p>&bull; إسهال.</p><p>&bull; الإمساك.</p><p>&bull; تغييرات في اختبارات الدم من وظائف الكبد.</p><p>&bull; تكوين خلايا الكبد الدهنية.</p><p>&bull; ألم عضلي.</p><p>&bull; التغيرات الحسية (بما في ذلك اضطراب الذوق وخدر أو وخز في الجلد).</p><p>&bull; زيادة خطر الجلطات الدموية (بما في ذلك الجلطات في الأوعية الصغيرة).</p><p>&nbsp;</p><p><u>غير شائعة</u> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص تم علاجه)</p><p>&bull; مشاكل الدم. هذا يمكن أن يجعلك أكثر كدمات بسهولة ، أو يصاب بالتهابات خطيرة ، أو تشعر بالتعب الشديد أو</p><p>&nbsp;&nbsp;&nbsp;لاهث.</p><p>&bull; التغييرات في رؤيتك وصعوبة الرؤية.</p><p>&bull; تورم البنكرياس. هذا قد يسبب ألما معتدلا إلى شديد في المعدة.</p><p>&bull; التغيير في كمية الكالسيوم في دمك. قد تشمل العلامات الشعور بالغثيان ، أو المرض</p><p>&nbsp;&nbsp;&nbsp;الكثير أو العطش. أخبر طبيبك إذا حدث هذا لأنه قد ترغب في الحصول على فحص الدم&nbsp;&nbsp;.</p><p>&bull; التهاب الرئتين. قد تكون الأعراض مثل الالتهاب الرئوي (مثل الشعور بضيق في التنفس و</p><p>&nbsp;&nbsp;&nbsp;يسعل).</p><p>&bull; تليف الكبد (مشاكل في الكبد).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>نادرة</u> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص تم علاجه)</p><p>&nbsp;</p><p>&bull; مشاكل الدم الحادة. هذا قد يؤدي إلى الحصول على كدمات بسهولة، أو يصاب بالتهابات خطيرة ، أو تشعر بالتعب الشديد</p><p>&nbsp;&nbsp;&nbsp;أو لاهث.</p><p>&bull; يتغير إلى قرنية عينيك.</p><p>&bull; مشاكل في العصب الذي يربط شبكية العين بعقلك.</p><p>&bull; تورم العصب البصري.</p><p>&bull; في بعض الحالات ، حدثت أمراض الكبد الأكثر حدة والتي توفي منها بعض المرضى. هذه</p><p>&nbsp;&nbsp;&nbsp;الأمراض تشمل التهاب الكبد ، تليف الكبد ، تلف خلايا الكبد ، انخفاض تكوين الصفراء ، و</p><p>&nbsp;&nbsp;&nbsp;فشل الكبد. قد تشمل الأعراض شعورًا عامًا بالتوعك ، مع أو بدون اليرقان</p><p>&nbsp;&nbsp;&nbsp;(اصفرار الجلد والعينين).</p><p>&bull; طفح جلدي شديد مع ظهور بثور أو تقشير في الجلد وربما بثور في الفم والأنف</p><p>(Stevens-<br />&nbsp; Johnson syndrome)</p><p>&nbsp;&nbsp;&nbsp;متلازمة جونسون).</p><p>&bull; تلف في الأوعية الدموية مما تسبب في النقاط الحمراء أو الأرجواني في الجلد.</p><p>&bull; اضطراب الجلد الحاد. وتشمل الأعراض احمرار ، تقرحات وتقشير.</p><p>الخلايا الموجودة عادة في بطانة الرحم الموجودة في مكان آخر من الجسم ، الخراجات على المبايض ،</p><p>&nbsp;&nbsp;&nbsp;والسرطان (يتم إعطاء علامات هذا أعلاه).</p><p>&bull; الكتلة غير السرطانية في البطانة الداخلية للمهبل (تسمى الورم المهبلي).</p><p>&bull; في بداية العلاج ، تفاقم أعراض سرطان الثدي مثل الزيادة في</p><p>&nbsp;&nbsp;&nbsp;قد يحدث ألم و / أو زيادة في حجم الأنسجة المصابة (المعروفة باسم اشتعال الورم).</p><p>&nbsp;</p><p><u>نادرة جدًّا</u> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص تم علاجه)</p><p>&bull; التهاب الجلد الذي يتميز بالطفح الجلدي أو الحمامي ، وغالبًا في المناطق المعرضة للضوء (أ</p><p>&nbsp;&nbsp;&nbsp;حالة تسمى الذئبة الحمامية الجلدية)</p><p>&bull; حالة الجلد التي تتميز بثور الجلد في المناطق المعرضة للضوء ، وهذا بسبب الزيادة</p><p>&nbsp;&nbsp;&nbsp;إنتاج الكبد لمجموعة خاصة من أصباغ الخلايا (تسمى البورفيرين)</p><p>&bull; استدعاء الإشعاع - طفح جلدي يتضمن احمرار وتورم و / أو ظهور تقرحات (مثل حروق الشمس الشديدة)</p><p>&nbsp;&nbsp;&nbsp;الجلد بعد تلقي العلاج الإشعاعي.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا لاحظت أية آثار جانبية، يُرجى التواصل مع طبيبك أو الصيدلي الخاص بك. ينطبق هذا أيضًا على التفاعلات العكسية غير المُدرَجة في نشرة العبوة هذه. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا المنتج الدَّوائي بعيدًا عن متناول الأطفال.</p><p>&nbsp;</p><p>يجب عليك عدم استخدام هذا المنتج الدَّوائي بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية المطوية وعبوة الشرائط بعد كلمة &quot;use by&quot; / &quot;يستخدم قبل&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المُحدد.</p><p>&nbsp;</p><p>لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية. يُحفَظ بعيدًا عن الضوء.</p><p>&nbsp;</p><p>لا تتخلص من أي منتجات دوائية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من المنتجات الدوائية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;المادة الفعالة هي سترات التاموكسيفين.</p><p>&nbsp;يحتوي القرص المغلف الواحد على 15.2 مجم من سترات التاموكسيفين (ما يُعادل 10 مجم تاموكسيفين).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p>سليلوز دقيق التَّبلور ، لاكتوز أحادي الهيدرات، ستيرات الماغنسيوم (هيئة دستور الأدوية الأوروبي)، نشا الذرة، السيليكا الغروية اللامائيز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الأقراص المغلَّفة عبارة عن أقراص دائرية ومحدبة، ذات لون أبيض.</p><p>&nbsp;</p><p>يتوافر عقار تاموكسيفين &quot;إيبيفيه&quot; 10 مجم في عبوات تحتوي على 30 أو 100 قرص مغلف.</p><p>&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التَّسويق</strong></p><p dir="RTL">&nbsp;شركة إيبيفيه فارما المحدودة NFG. شراكة محدودة</p><p dir="RTL">&nbsp;أونتراخ،</p><p dir="RTL">النمسا</p><p>&nbsp;</p><p><strong>جهة التَّصنيع</strong></p><p>شركة هاوبت فارما أماريج المحدودة</p><p>378 شارع دوناوستاوف</p><p>93055 ريجنسبورج</p><p>ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tamoxifen “Ebewe” 10mg Film-Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 15.2 mg tamoxifen citrate (corresponding to 10 mg tamoxifen).
Other excipients with known effect: Lactose monohydrate and lactose
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets 
White, round, convex.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&#39;Tamoxifen&#39; is indicated for:</p><p>1. The treatment of breast cancer.</p><p>2. The treatment of anovulatory infertility.</p><p>3. The primary prevention of breast cancer in women at moderate or high risk (see section 5.1)</p><p>Women aged less than 30 years old were excluded from primary prevention trials so the efficacy and safety of tamoxifen treatment in these younger women is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>1. Breast cancer:</em></strong></p><p><strong>Adults:</strong>&nbsp;The recommended daily dose of tamoxifen is normally 20mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30-40mg per day is not available, although these doses have been used in some patients with advanced disease.</p><p><strong><em>Elderly people:</em></strong>&nbsp;Similar dosing regimens of tamoxifen have been used in older people with breast cancer and in some of these patients it has been used as sole therapy.</p><p><strong><em>2. Anovulatory infertility:</em></strong></p><p>Before commencing any course of treatment, whether initial or subsequent, the possibility of pregnancy must be excluded. In women who are menstruating regularly, but with anovular cycles, the initial course of treatment consists of 20 mg given daily on the second, third, fourth and fifth days of the menstrual cycle. If unsatisfactory basal temperature records or poor pre-ovulatory cervical mucus indicate that this initial course of treatment has been unsuccessful, further courses may be given during subsequent menstrual periods, increasing the dosage to 40mg and then 80mg daily.</p><p>In women who are not menstruating regularly, the initial course may begin on any day. If no signs of ovulation are demonstrable, then a subsequent course of treatment may start 45 days later, with dosage increased as above. If a patient responds with menstruation, then the next course of treatment is commenced on the second day of the cycle.</p><p><strong>3. Primary prevention of breast cancer</strong></p><p>Tamoxifen treatment for the primary prevention of breast cancer should only be initiated by a medical practitioner experienced in prescribing for this indication, and as part of a shared care pathway arrangement, with appropriate patient identification, management and follow up.</p><p>The recommended dose is 20 mg daily for 5 years for those women at moderate or high risk. There are insufficient data to support a higher dose or longer period of use.</p><p>Before commencing treatment, an assessment of the potential benefits and risks is essential, including calculating a patient&#39;s risk of developing breast cancer according to local guidelines and risk assessment tools. Validated algorithms are available that calculate breast cancer risk based on features such as age, family history, genetic factors, reproductive factors and history of breast disease.</p><p>The use of tamoxifen should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account her risk of breast cancer.</p><p><strong>Paediatric population</strong></p><p>The use of tamoxifen is not recommended in children. The safety and efficacy of tamoxifen in children has not yet been established (see sections 5.1 and 5.2).</p><p><strong><u>Method of administration</u></strong></p><p>For administration by the oral route.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                General contraindications (all indications)
Tamoxifen should not be used in the following:
• Pregnancy. Pre-menopausal patients must be carefully examined before treatment for all indications to exclude the possibility of pregnancy (see also section 4.6).
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Concurrent anastrozole therapy (see section 4.5).
Treatment for infertility
Tamoxifen should not be used in:
• Patients with a personal or family history of confirmed idiopathic venous thromboembolic events or a known genetic defect.
Primary prevention of breast cancer
Tamoxifen should not be used in:
• Women with a history of deep vein thrombosis or pulmonary embolus.
• Women who require concomitant coumarin-type anticoagulant therapy (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The warnings and precautions for use are different depending on the indication being treated. The specific warnings and precautions for the primary prevention of breast cancer can be found at the end of the section.</p><p>Menstruation is suppressed in a proportion of premenopausal women receiving tamoxifen for the treatment of breast cancer.</p><p>An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumors), has been reported in association with tamoxifen treatment. The underlying mechanism is unknown but may be related to the estrogen-like effect of tamoxifen.</p><p>There is also the general risk for endometrial cancer with increasing age. Any patient receiving or having previously received tamoxifen who reports abnormal gynecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.</p><p>A number of second primary tumors, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.</p><p><u>Venous thromboembolism (VTE)</u></p><p>&bull; A two- to three-fold increase in the risk for VTE has been demonstrated in healthy tamoxifen-treated women (see section 4.8).</p><p>&bull; In patients with breast cancer, prescribers should obtain careful histories with respect to the patient&#39;s personal and family history of VTE. If suggestive of a prothrombotic risk, patients should be screened for thrombophilic factors. Patients who test positive should be counselled regarding their thrombotic risk. The decision to use tamoxifen in these patients should be based on the overall risk to the patient. In selected patients, the use of tamoxifen with prophylactic anticoagulation may be justified (cross reference section 4.5).</p><p>&bull; The risk of VTE is further increased by severe obesity, increasing age and all other risk factors for VTE. The risks and benefits should be carefully considered for all patients before treatment with tamoxifen. In patients with breast cancer, this risk is also increased by concomitant chemotherapy (see section 4.5). Long-term anticoagulant prophylaxis may be justified for some patients with breast cancer who have multiple risk factors for VTE.</p><p>&bull; Surgery and immobility: For patients being treated for infertility, tamoxifen should be stopped at least 6 weeks before surgery or long-term immobility (when possible) and re-started only when the patient is fully mobile. For patients with breast cancer, tamoxifen treatment should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupting treatment. All patients should receive appropriate thrombosis prophylactic measures and should include graduated compression stockings for the period of hospitalization, early ambulation, if possible, and anticoagulant treatment.</p><p>&bull; If any patient presents with VTE, tamoxifen should be stopped immediately and appropriate anti-thrombosis measures initiated. In patients being treated for infertility, tamoxifen should not be re-started unless there is a compelling alternative explanation for their thrombotic event. In patients receiving tamoxifen for breast cancer, the decision to re-start tamoxifen should be made with respect to the overall risk for the patient. In selected patients with breast cancer, the continued use of tamoxifen with prophylactic anticoagulation may be justified.</p><p>&bull; All patients should be advised to contact their doctors immediately if they become aware of any symptoms of VTE.</p><p>In delayed microsurgical breast reconstruction Tamoxifen may increase the risk of microvascular flap complications.</p><p>In an uncontrolled trial in 28 girls aged 2&ndash;10 years with McCune Albright Syndrome (MAS), who received 20 mg once a day for up to 12 months duration, mean uterine volume increased after 6 months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established (see section 5.1).</p><p>In the literature it has been shown that CYP2D6 poor metabolisers have a lowered plasma level of endoxifen, one of the most important active metabolites of tamoxifen (see section 5.2).</p><p>Concomitant medications that inhibit CYP2D6 may lead to reduced concentrations of the active metabolite endoxifen. Therefore, potent inhibitors of CYP2D6 (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided during tamoxifen treatment (see section 4.5 and 5.2).</p><p>Tamoxifen contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Radiation recall has been reported very rarely in patients on Tamoxifen who have received prior radiotherapy. The reaction is usually reversible upon temporary cessation of therapy and re-challenge may result in a milder reaction. Treatment with Tamoxifen was continued in most cases.</p><p><u>Additional precautions relating to primary reduction of breast cancer risk</u></p><p>Tamoxifen therapy for this indication has uncommonly been associated with serious side effects such as pulmonary embolus and uterine cancer (both endometrial adenocarcinoma and uterine sarcoma). In trials comparing tamoxifen to placebo for reduction of the incidence of breast cancer in women at increased risk of breast cancer, the use of tamoxifen was associated with an increased risk of serious and sometimes fatal adverse events including endometrial cancer (approximately 4 cases per 1000 women over 5 years of use) and thromboembolic events (including deep vein thrombosis and pulmonary embolism). Less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities and gynecological conditions may also occur. Non-gynecological conditions such as cataracts were also increased (see section 4.8). Whether the benefits of treatment are considered to outweigh the risks depends on the woman&#39;s age, health history, and level of breast cancer risk (see sections 4.4, 4.8 and 5.1).</p><p>In the primary prevention studies, due to the limited number of patients with a confirmed BRCA mutation there is uncertainty about the absolute benefit in these patients treated with tamoxifen for primary prevention of breast cancer.</p><p>Benign gynecological conditions (including endometrial polyps, endometriosis, and ovarian cysts) and gynecological procedures (including hysteroscopy, dilation and curettage, and hysterectomy) were also found to occur more frequently with tamoxifen use.</p><p>Any women receiving or having previously received tamoxifen for risk reduction should be promptly investigated if any abnormal gynecological symptoms develop, especially non-menstrual vaginal bleeding.</p><p>The risks of tamoxifen therapy are generally lower in younger women than in older women. In the primary prevention trials, in contrast to women aged 50 years or older, women younger than 50 years did not have an increased risk of endometrial cancer or pulmonary embolism and the increased risk of deep vein thrombosis was small and restricted to the treatment period.</p><p>When considered for primary reduction of breast cancer risk, tamoxifen is contraindicated in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus (see sections 4.3 and 4.5). In women who do not have a history of thromboembolic events, but who are at increased risk of thromboembolic events, the benefits and risks of tamoxifen for the primary reduction of breast cancer risk should be carefully considered. Risk factors for thromboembolic events include smoking, immobility and a family history of venous thrombosis; an additional risk factor, is concomitant oral contraceptive or hormone replacement therapy, which is not recommended in women taking tamoxifen. In women receiving tamoxifen for primary reduction of breast cancer risk, tamoxifen should be stopped approximately 6 weeks before undergoing elective surgery to reduce the risk of thromboembolic events. Consideration should also be given to discontinuing tamoxifen during periods of immobility.</p><p>The use of tamoxifen for reduction of breast cancer risk has been associated with reduced bone density in premenopausal women. Whether this may result in an increased risk of fracture is not known. Pre-menopausal women taking tamoxifen for this reason should be advised regarding measures to maintain bone health.</p><p><u>Excipient warnings</u></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When tamoxifen is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration is initiated, careful monitoring of the patient is recommended.</p><p>When tamoxifen is used in combination with cytotoxic agents for the treatment of breast cancer, there is increased risk of thromboembolic events occurring (see also sections 4.4 and 4.8). Because of this increase in risk of VTE, thrombosis prophylaxis should be considered for these patients for the period of concomitant chemotherapy.</p><p>The use of tamoxifen in combination with anastrozole as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone.</p><p>As tamoxifen is metabolized by cytochrome P450 3A4, care is required when co- administering with drugs, such as rifampicin, known to induce this enzyme as tamoxifen levels may be reduced. The clinical relevance of this reduction is unknown.</p><p>Pharmacokinetic interaction with CYP2D6 inhibitors, showing a reduction in plasma level of an active tamoxifen metabolite, 4-hydroxy-Ndesmethyl-tamoxifen (endoxifen), has been reported in the literature.</p><p>Pharmacokinetic interaction with CYP2D6 inhibitors, showing a 65-75% reduction in plasma levels of one of the more active forms of the drug, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine) in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided (see section 4.4 and 5.2).</p><p><strong>Primary prevention of breast cancer risk</strong></p><p>In women receiving tamoxifen for the primary prevention of breast cancer, the use of coumarin type anticoagulants is contraindicated (see sections 4.3 and 4.4).</p><p>There is some evidence that hormone replacement therapy may reduce the effectiveness of tamoxifen, and the concomitant use of tamoxifen and oral hormonal contraceptives is not recommended. Therefore, the use of hormone replacement therapy or oral hormonal contraceptives to manage tamoxifen side effects is not recommended (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential</strong></p><p>Women should be advised not to become pregnant whilst taking tamoxifen and should use barrier or other adequate non-hormonal contraceptive methods if sexually active. Premenopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be informed of the potential risks to the fetus, should they become pregnant whilst taking tamoxifen or within two months of cessation of therapy.</p><p><u>Pregnancy</u></p><p>Tamoxifen must not be administered during pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and fetal deaths after women have taken tamoxifen, although no causal relationship has been established.</p><p>Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.</p><p>In rodent models of fetal reproductive tract development, tamoxifen was associated with changes similar to those caused by estradiol, ethynyl estradiol, clomiphene and diethylstilbestrol (DES). Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES in-utero and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix. Only a small number of pregnant women have been exposed to tamoxifen. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed in utero to tamoxifen.</p><p><u>Breast-feeding</u></p><p>It is not known if tamoxifen is excreted in human milk and therefore the drug is not recommended during breast-feeding. The decision either to discontinue nursing or discontinue tamoxifen should take into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tamoxifen is unlikely to impair the ability of patients to drive or operate machinery. However, fatigue has been reported with the use of tamoxifen and caution should be observed when driving or using machinery while such symptoms persist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tabulated list of adverse reactions</u></p><p>The following definitions apply to the incidence of undesirable effects: Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women patients with operable breast cancer treated for 5 years and unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication. The safety findings in the breast cancer prevention trials appeared consistent overall with the established safety profile of tamoxifen.</p><p>Table 1 Adverse Drug Reactions (ADR) by System Organ Class (SOC) and Frequency.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>SOC</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Adverse Drug Reaction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uterine fibroids</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Endometrial cancer</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uterine Sarcoma (mostly malignant mixed Mullerian tumours)<sup>a</sup></p><p>Tumour Flare<sup>a</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fluid retention</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypercalcaemia (in patients with bony metastases)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ischaemic cerebrovascular events</p><p>Headache</p><p>Light headedness</p><p>Sensory disturbances (including paraesthesia and dysgeusia)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Optic neuritis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cataracts</p><p>Retinopathy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Visual disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Corneal changes</p><p>Optic neuropathy<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Hot flushes</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thromboembolic events (including deep vein thrombosis, microvascular thrombosis and pulmonary embolism)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Interstitial pneumonitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Diarrhoea</p><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Changes in liver enzymes</p><p>Fatty liver</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cirrhosis of the liver</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis<sup>a</sup></p><p>Cholestasis<sup>a</sup></p><p>Hepatic failure<sup>a</sup></p><p>Hepatocellular injury<sup>a</sup></p><p>Hepatic necrosis<sup>a</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Skin Rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema<sup>a</sup></p><p>Steven-Johnsons syndrome<sup>a</sup></p><p>Cutaneous vasculitis<sup>a</sup></p><p>Bullous pemphigoid<sup>a</sup></p><p>Erythema multiforme<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythematosus<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leg cramp</p><p>Myalgia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vaginal bleeding</p><p>Vaginal discharge</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus valvae</p><p>Endometrial changes (including hyperplasia and polyps)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Endometriosis<sup>a</sup></p><p>Cystic ovarian swelling<sup>a</sup></p><p>Vaginal polyps</p></td></tr><tr><td style="vertical-align:top"><p>Congenital, familial and</p><p>genetic disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Porphyria cutanea tarda<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Elevated triglycerides</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Radiation Recall<sup>b</sup></p></td></tr></tbody></table><p><sup>a</sup>&nbsp;This adverse drug reaction was&nbsp;<u>not</u>&nbsp;reported in the tamoxifen arm (n= 3094) of the above study; however, it has been reported in other trials or from other sources. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size e.g. 3094). This is calculated as 3/3094 which equates to a frequency category of &#39;rare&#39;.</p><p><sup>b</sup>&nbsp;The event was not observed in other major clinical studies. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of &#39;very rare&#39;.</p><p>Side effects can be classified as either due to the pharmacological action of the drug, e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumor flare, or as more general side effects, e.g. gastrointestinal intolerance, headache, light-headedness and occasionally, fluid retention and alopecia.</p><p>When side effects are severe, it may be possible to control them by a simple reduction of dosage (to not less than 20 mg/day) without loss of control of the disease. If side effects do not respond to this measure, it may be necessary to stop the treatment.</p><p>Skin rashes (including rare reports of erythema multiforme, Stevens- Johnson syndrome, cutaneous vasculitis and bullous pemphigoid) and commonly hypersensitivity reactions including angioedema have been reported.</p><p>Uncommonly, patients with bony metastases have developed hypercalcemia on initiation of therapy.</p><p>Cases of visual disturbances, including rare reports of corneal changes, and common reports of retinopathy have been described in patients receiving tamoxifen therapy. Cataracts have been reported commonly in association with the administration of tamoxifen.</p><p>Cases of optic neuropathy and optic neuritis have been reported in patients receiving tamoxifen and, in a small number of cases, blindness has occurred.</p><p>Sensory disturbances (including paranesthesia and dysgeusia) have been reported commonly in patients receiving tamoxifen.</p><p>Uterine fibroids, endometriosis and other endometrial changes including hyperplasia and polyps have been reported.</p><p>Falls in platelet count, usually to 80,000 to 90,000 per cu mm but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.</p><p>Leucopenia has been observed following the administration of tamoxifen, sometimes in association with anemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe, and very rarely cases of agranulocytosis have been reported.</p><p>There is evidence of ischemic cerebrovascular events and thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism, occurring commonly during tamoxifen therapy (see sections 4.3, 4.4 and 4.5). When tamoxifen is used in combination with cytotoxic agents, there is an increased risk of thromboembolic events occurring.</p><p>Leg cramps and myalgia have been reported commonly in patients receiving tamoxifen.</p><p>Uncommonly, cases of interstitial pneumonitis have been reported.</p><p>Tamoxifen has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis, and, hepatocellular injury (including hepatic necrosis).</p><p>Commonly, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen.</p><p>Cystic ovarian swellings have rarely been observed in women receiving tamoxifen.</p><p>Vaginal polyps have rarely been observed in women receiving tamoxifen.</p><p>Cutaneous lupus erythematosus has been observed very-rarely in patients receiving tamoxifen.</p><p>Porphyria cutanea tarda has been observed very-rarely in patients receiving tamoxifen.</p><p>Fatigue has been reported very commonly in patients taking tamoxifen.</p><p>Radiation Recall has been observed very rarely in patients receiving tamoxifen.</p><p>Uncommonly incidences of endometrial cancer and rare instances of uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen treatment.</p><p><u>Primary prevention of breast cancer risk</u></p><p>The most common adverse events reported from studies in women at increased risk of breast cancer, and occurring more frequently during treatment with tamoxifen than with placebo, were those associated specifically with the pharmacological action of tamoxifen such as vasomotor symptoms (hot flushes, night sweats), menstrual abnormalities\irregularities, vaginal discharge, and vaginal dryness.</p><p>In the primary prevention trials tamoxifen significantly increased the incidence of endometrial cancer, deep vein thrombosis, and pulmonary embolism compared with placebo, but the absolute increase in risk was small. The risk of developing cataracts was also significantly increased with tamoxifen.</p><p><u>Women under 50 years old</u></p><p>A meta-analysis of risk reduction trials stratified by age showed that while women over 50 years old at randomization had a significantly increased risk of endometrial cancer compared with placebo (RR 3.32, 95% CI 1.95-5.67; p&lt;0.0001), women aged under 50 years did not (RR 1.19, 95% CI 0.53-2.65; p=0.6). Similarly, women under 50 years did not have a significantly increased risk of pulmonary embolism compared with placebo (RR 1.16, 95% CI 0.55-2.43; p=0.60) and their risk of deep vein thrombosis was only significantly increased during the active treatment phase (RR 2.30, 95% CI 1.23- 4.31; p=0,009) but not after treatment had ended.</p><p><u>Gynecological conditions and procedures</u></p><p>In placebo-controlled trials of the use of tamoxifen for the primary reduction of breast cancer risk, benign gynecological conditions and procedures were more commonly reported with tamoxifen. The IBIS-1 trial found that in 3573 women taking tamoxifen compared to 3566 women on placebo, the following gynaecological conditions and procedures were more common in women taking tamoxifen: abnormal bleeding (842 v 678, p&lt;00001); endometrial polyps (130 v 65, p&lt;0,0001); ovarian cysts (101 v 42, p&lt;00001); hysteroscopy (228 v 138, P&lt;0,0001); pelvic ultrasound (209 v 132, p&lt;00001); dilation and curettage (178 v 94, p&lt;00001); hysterectomy (154 v 104, p=0002) and oophorectomy (103 v 67, p=0006).</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via NPC-SFDA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>On theoretical grounds an overdosage would be expected to cause enhancement of the pharmacological side-effects mentioned above. Observations in animals show that extreme overdosage (100 - 200 times recommended daily dose) may produce estrogenic effects.</p><p>There have been reports in the literature that tamoxifen given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.</p><p>There is no specific antidote to overdosage, and treatment must be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-estrogens. ATC code: L02BA01.</p><p>Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of estrogen antagonist and estrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumor level, tamoxifen acts primarily as an antiestrogen, preventing estrogen binding to the estrogen receptor. In the clinical situation, it is recognized that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10 - 20%. Tamoxifen does not adversely affect bone mineral density.</p><p>There are no long-term safety data in children. In particular, the long-term effects of tamoxifen on growth, puberty and general development have not been studied.</p><p>CYP2D6 polymorphism status may be associated with variability in clinical response to tamoxifen. The poor metabolizer status may be associated with reduced response. The consequences of the findings for the treatment of CYP2D6 poor metabolizers have not been fully elucidated (see sections 4.4, 4.5 and 5.2).</p><p><u>CYP2D6 genotype</u></p><p>Available clinical data suggest that patients, who are homozygote for non-functional CYP2D6 alleles, may experience reduced effect of tamoxifen in the treatment of breast cancer.</p><p>The available studies have mainly been performed in postmenopausal women (see sections 4.4 and 5.2)</p><p>Primary reduction of breast cancer risk</p><p>Tamoxifen reduces, but does not eliminate the risk of breast cancer. In clinical trials, tamoxifen decreased the incidence of estrogen receptor-positive tumors, but did not alter the incidence of estrogen receptor-negative tumors. The use of tamoxifen should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account her risk of breast cancer.</p><p><u>Concomitant use of Hormone Replacement Therapy</u></p><p>The concomitant use of tamoxifen and hormone replacement therapy is not recommended for primary prevention of breast cancer based on results of IBIS-1 trial.</p><p><u>Effects of age and menopausal status</u></p><p>No age-related effects of tamoxifen on breast cancer incidence were reported in the trials.</p><p><strong>5.2 Pharmacokinetic properties</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration, tamoxifen is absorbed rapidly with maximum serum concentrations attained within 4&ndash;7 hours. Steady state concentrations (about 300ng/ml) are achieved after four weeks treatment with 40mg daily. The drug is highly protein bound to serum albumin (&gt;99%). Metabolism is by hydroxylation, demethylation and conjugation, giving rise to several metabolites which have a similar pharmacological profile to the parent compound and thus contribute to the therapeutic effect. Excretion occurs primarily via the feces and an elimination half-life of approximately seven days has been calculated for the drug itself, whereas that for<strong>&nbsp;</strong>N-desmethyltamoxifen, the principal circulating metabolite, is 14 days.</p><p>In a clinical study where girls between 2 and 10 years with McCune Albright Syndrome (MAS) received 20mg tamoxifen once a day for up to 12 months duration, there was an age-dependent decrease in clearance and an increase in exposure (AUC), (with values up to 50% higher in the youngest patients) compared with adults.</p><p>Tamoxifen is metabolised mainly via CYP3A4 to N-desmethyl-tamoxifen, which is further metabolised by CYP2D6 to another active metabolite endoxifen. In patients who lack the enzyme CYP2D6 endoxifen concentrations are approximately 75% lower than in patients with normal CYP2D6 activity. Administration of strong CYP2D6 inhibitors reduces endoxifen circulating levels to a similar extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tamoxifen was not mutagenic in a range of in vitro and in vivo mutagenicity tests. Tamoxifen was genotoxic in some in-vitro and in-vivo genotoxicity tests in rodents. Gonadal tumors in mice and liver tumors in rats receiving tamoxifen have been reported in long term studies. The clinical relevance of these findings has not been established.</p><p>Tamoxifen is a drug on which extensive clinical experience has been obtained.</p><p>Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li><ul><li>Microcrystalline cellulose</li><li>Lactose monohydrate</li><li>Magnesium stearate</li><li>Maize starch</li><li>Colloidal anhydrous silica</li></ul></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p><p>Store in the original container in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>PVC/PVDC/aluminium blister packs</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Packs of 30 and 100 film-coated tablets</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE PHARMA GES.M.B.H NFG. KG , 
UNTERACH, 
AUSTRIA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>